Precision BioSciences, BMO Capital
HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has ...
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
DURHAM, N.C., January 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...
(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...
3d
BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback